Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay
April 04 2014 - 8:15AM
Marketwired
Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay
Covers Method of Identifying Tumor of Origin in Cancer of
Unknown Primary or Metastatic Cancer; Expands Company's Leading IP
Position in the Growing Area of microRNA Biomarkers
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Apr 4, 2014) -
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics and therapeutics,
today announced that the Company received a Notice of Allowance
from the United States Patent and Trademark Office (USPTO) for a
patent covering the method of use of a core element of Rosetta
Genomics' microRNA technology in the identification of the tumor of
origin in cancer of unknown or uncertain primary and metastatic
cancer. The issued claims for U.S. Patent Application No.
13/167,489 is entitled "Gene Expression Signature for
Classification of Tissue of Origin of Tumor Samples."
The invention covered by this patent relates to the methods for
determining an expression profile with a primer sequence and the
comparison of the expression profile that quantitates 48 microRNAs
and assigns one of 25 tumor diagnoses using a biologically
motivated binary decision tree and a K-Nearest Neighbors classifier
to identify the tumor of origin. This patent protects the
intellectual property of the Company's first generation Cancer
Origin Test, which utilizes a polymerase chain reaction (PCR)
technology for sequencing.
"We are pleased to expand our intellectual property portfolio
with this new U.S. patent. While this patent covers our first
generation assay, it is still critical to our patent strategy as it
creates a barrier to entry for would-be competitors and solidifies
our position as the leader in microRNA biomarker technology and
microRNA-based diagnostics," noted Kenneth A. Berlin, President and
Chief Executive Officer of Rosetta Genomics. "This patent is
important as it protects key elements of our microRNA technology
and could be indicative of the future receipt of patent protection
for our other existing and future assays. We continue to build
a strong intellectual property position to protect our expanding
portfolio of microRNA-based diagnostics and
therapeutics."
About Rosetta Cancer Testing Services Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S.
alone, Rosetta Genomics estimates that 200,000 patients a year may
benefit from the Rosetta Cancer Origin Test™, 60,000 from the
Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer
Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The
Company's assays are offered directly by Rosetta Genomics in the
U.S., and through distributors around the world. For more
information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at
(215) 382-9000 ext.
309.
About Rosetta Genomics Founded in 2000, Rosetta's integrative
research platform combining bioinformatics and state-of- the-art
laboratory processes has led to the discovery of hundreds of
biologically validated novel human microRNAs. Building on its
strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools and therapeutics. Rosetta currently commercializes
a full range of microRNA-based molecular diagnostics. Rosetta's
cancer testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. For more
information, please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test™, Rosetta's development or commercialization of molecular
diagnostics, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test™, Rosetta's
development of personalized medicine products and services, Rosetta
achieving further patent protection for its existing and future
assays and Rosetta building a strong intellectual property
position, constitute forward-looking statements for the purposes of
the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta's Annual Report
on Form 20-F for the year ended December 31, 2012 as filed with the
SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
Company Contact: Rosetta Genomics Ken Berlin President & CEO
(609) 419-9003
investors@rosettagenomics.com Investor Contacts: LHA Anne Marie
Fields (212) 838-3777
afields@lhai.com or Bruce Voss (310) 691-7100
bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024